1. A method for assessing protein expression levels in a systemic lupus erythematosus (SLE) patient comprising:(a) obtaining a blood, serum or plasma sample from the SLE patient;
(b) assessing protein expression levels of at least one cytokine from each of (i), (ii), (iii), and (iv), wherein (i) is an innate-type cytokine selected from an interleukin-1 alpha (IL-1?), an interleukin-1 beta (IL-1?), an interferon-alpha (IFN-?), interferon-beta (IFN-?), a granulocyte-colony stimulating factor 3 (G-CSF), interleukin-7 (IL-7), and an interleukin-15 (IL-15), (ii) is a T-helper type-1 (Th1) cytokine selected from an interleukin-2 (IL-2), an interleukin-12 (IL-12), and an interferon-gamma (IFN-?), (iii) is a T-helper type-2 (Th2) cytokine selected from an interleukin-4 (IL-4), an interleukin-5 (IL-5), and an interleukin-13 (IL-13), and (iv) is a T-helper type-17 (Th17) cytokine selected from an interleukin-6 (IL-6), an interleukin-17A (IL-17A), an interleukin-21 (IL-21), and an interleukin-23 (IL-23); and
(c) assessing protein expression levels of each molecule from each of (v), (vi), (vii), and (viii), wherein (v) comprises the following chemokine(s) or adhesion molecules: a CXC motif chemokine ligand 8 (CXCL8)/interleukin-8 (IL-8), a CXC motif chemokine ligand 10 (CXCL10)/IFN-gamma-inducible protein 10 (IP-10), one or both of a CC motif chemokine ligand 5 (CCL5) and regulated on activation normal T cell expressed and secreted (RANTES), a CC motif chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1), a CC motif chemokine ligand 7 (CCL7)/monocyte chemoattractant protein-3 (MCP-3), a CC motif chemokine ligand 3 (CCL3)/macrophage inflammatory protein-1 alpha (MIP-1?), a CC motif chemokine ligand 4 (CCL4)/macrophage inflammatory protein-1 beta (MIP-1?), a CXC motif chemokine ligand 1 (CXCL1)/growth-regulated oncogene-alpha (GRO-?), a CXC motif chemokine ligand 9 (CXCL9)/monokine induced by interferon-gamma (MIG), an eotaxin, an Intercellular Adhesion Molecule 1 (ICAM-1), and an E-selectin, (vi) comprises the following tumor necrosis factor receptor (TNFR) superfamily member molecules: a tumor necrosis factor alpha (TNF-?), a tumor necrosis factor receptor I (TNFRI), a tumor necrosis factor receptor II (TNFRII), a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a first apoptosis signal (Fas), a first apoptosis signal ligand (FasL), a B-lymphocyte stimulator (BLyS), a proliferation-inducing ligand (APRIL), and a nerve growth factor-beta (NGF?), (vii) comprises the following regulatory mediator molecules: an interleukin-10 (IL-10), a transforming growth factor beta (TGF-?), a CXC motif chemokine ligand 12 (CXCL12)/stromal cell-derived factor 1 (SDF-1), and an interleukin-1 receptor antagonist (IL-1RA), and (viii) comprises the following systemic lupus erythematosus (SLE) mediator molecules: a leukemia inhibitor factor (LIF), a plasminogen activator inhibitor-1 (PAI-1), a platelet-derived growth factor subunit beta homodimer (PDGF-BB), a leptin, a stem cell factor (SCF), and an interleukin-2 receptor alpha chain (IL-2RA).